Interview with Carlos Kiffer, President, GC-2
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ
Tel: (21) 2159-2600
Web: http://www.bago.com.br/web/cgi/cgilua.exe/sys/start.htm?tpl=home
With an innovative profile, Bagó Group is a leader in healthcare in Latin America. It is formed by a pool of solid enterprises, oriented around healthcare and improving quality of life.
Proud to be Latin American, the group was founded in 1934 in Argentina, and today is one of the most significant in the world pharmaceutical market. With an outstanding presence in Latin America and extending its roots over the world, it counts on over 6500 employees that share the same values of innovation and the same ideals of growth.
Laboratórios Bagó was established in Brazil in 2002, with the aim of working in the pharmaceutical industry as a tool for building a strong laboratory, and now counts a multidisciplinary team composed by over 180 professionals.
It is an intellectual leader, a reference in the Marketing business and has worked with Merck, Glaxo and Roche Laboratories.
Hydrophilic Array, Trifamox IBL, Magnesium Valproate, Alprazolam Sublingual, Talniflumate
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
See our Cookie Privacy Policy Here
